The Claim
In adults with obesity or overweight, once-weekly administration of tirzepatide at doses of 5, 10, or 15 mg for 72 weeks reduces serum uric acid levels by 0.69 to 0.95 mg/dL compared to a 0.18 mg/dL reduction with placebo, with the greatest reduction observed at the 15 mg dose.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity or overweight, a weekly injection of tirzepatide at doses of 5, 10, or 15 mg for 72 weeks lowers blood uric acid levels more than a placebo, with the highest dose producing the greatest reduction.
See the scientific wording
In adults with obesity or overweight, once-weekly tirzepatide at doses of 5, 10, or 15 mg for 72 weeks reduces serum uric acid levels by 0.69 to 0.95 mg/dL, compared to a 0.18 mg/dL reduction with placebo, with the greatest effect seen at the highest dose, suggesting a clinically meaningful impact on hyperuricemia.
Losing body fat decreases the breakdown of purines that make uric acid and improves how the kidneys remove uric acid from the blood by fixing insulin-related problems in the kidney tubes.
What the research says
1 studyIn people with excess weight, a weekly shot called tirzepatide lowered a substance in the blood called uric acid — which can cause gout — by nearly 1 point, while placebo barely moved it. The higher the dose, the more uric acid dropped.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.